180 related articles for article (PubMed ID: 22012889)
1. A framework to select clinically relevant cancer cell lines for investigation by establishing their molecular similarity with primary human cancers.
Dancik GM; Ru Y; Owens CR; Theodorescu D
Cancer Res; 2011 Dec; 71(24):7398-409. PubMed ID: 22012889
[TBL] [Abstract][Full Text] [Related]
2. Validating the impact of a molecular subtype in ovarian cancer on outcomes: a study of the OVCAD Consortium.
Pils D; Hager G; Tong D; Aust S; Heinze G; Kohl M; Schuster E; Wolf A; Sehouli J; Braicu I; Vergote I; Cadron I; Mahner S; Hofstetter G; Speiser P; Zeillinger R
Cancer Sci; 2012 Jul; 103(7):1334-41. PubMed ID: 22497737
[TBL] [Abstract][Full Text] [Related]
3. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
4. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue.
Shen SS; Smith CL; Hsieh JT; Yu J; Kim IY; Jian W; Sonpavde G; Ayala GE; Younes M; Lerner SP
Cancer; 2006 Jun; 106(12):2610-6. PubMed ID: 16700038
[TBL] [Abstract][Full Text] [Related]
5. Identifying distinct classes of bladder carcinoma using microarrays.
Dyrskjøt L; Thykjaer T; Kruhøffer M; Jensen JL; Marcussen N; Hamilton-Dutoit S; Wolf H; Orntoft TF
Nat Genet; 2003 Jan; 33(1):90-6. PubMed ID: 12469123
[TBL] [Abstract][Full Text] [Related]
6. p63 expression defines a lethal subset of muscle-invasive bladder cancers.
Choi W; Shah JB; Tran M; Svatek R; Marquis L; Lee IL; Yu D; Adam L; Wen S; Shen Y; Dinney C; McConkey DJ; Siefker-Radtke A
PLoS One; 2012; 7(1):e30206. PubMed ID: 22253920
[TBL] [Abstract][Full Text] [Related]
7. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
[TBL] [Abstract][Full Text] [Related]
8. Identification and Clinical Validation of a Novel 4 Gene-Signature with Prognostic Utility in Colorectal Cancer.
Ahluwalia P; Mondal AK; Bloomer C; Fulzele S; Jones K; Ananth S; Gahlay GK; Heneidi S; Rojiani AM; Kota V; Kolhe R
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387239
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer.
Kim WJ; Kim EJ; Kim SK; Kim YJ; Ha YS; Jeong P; Kim MJ; Yun SJ; Lee KM; Moon SK; Lee SC; Cha EJ; Bae SC
Mol Cancer; 2010 Jan; 9():3. PubMed ID: 20059769
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of microRNA-100 in patients with bladder cancer.
Cao YH; Zhang HH; Xu HF; Duan YJ; Li Q; Huang B
Genet Mol Res; 2015 Dec; 14(4):15948-54. PubMed ID: 26662386
[TBL] [Abstract][Full Text] [Related]
11. Establishment of a novel risk score model by comprehensively analyzing the immunogen database of bladder cancer to indicate clinical significance and predict prognosis.
Liu L; Hu J; Wang Y; Sun T; Zhou X; Li X; Ma F
Aging (Albany NY); 2020 Jun; 12(12):11967-11989. PubMed ID: 32570217
[TBL] [Abstract][Full Text] [Related]
12. Sonic hedgehog (Shh) signaling promotes tumorigenicity and stemness via activation of epithelial-to-mesenchymal transition (EMT) in bladder cancer.
Islam SS; Mokhtari RB; Noman AS; Uddin M; Rahman MZ; Azadi MA; Zlotta A; van der Kwast T; Yeger H; Farhat WA
Mol Carcinog; 2016 May; 55(5):537-51. PubMed ID: 25728352
[TBL] [Abstract][Full Text] [Related]
13. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.
Sanchez-Carbayo M; Socci ND; Lozano J; Saint F; Cordon-Cardo C
J Clin Oncol; 2006 Feb; 24(5):778-89. PubMed ID: 16432078
[TBL] [Abstract][Full Text] [Related]
14. Profiling the evolution of human metastatic bladder cancer.
Nicholson BE; Frierson HF; Conaway MR; Seraj JM; Harding MA; Hampton GM; Theodorescu D
Cancer Res; 2004 Nov; 64(21):7813-21. PubMed ID: 15520187
[TBL] [Abstract][Full Text] [Related]
15. Bladder cancer outcome and subtype classification by gene expression.
Blaveri E; Simko JP; Korkola JE; Brewer JL; Baehner F; Mehta K; Devries S; Koppie T; Pejavar S; Carroll P; Waldman FM
Clin Cancer Res; 2005 Jun; 11(11):4044-55. PubMed ID: 15930339
[TBL] [Abstract][Full Text] [Related]
16. miR-429 expression in bladder cancer and its correlation with tumor behavior and clinical outcome.
Wu CL; Ho JY; Hung SH; Yu DS
Kaohsiung J Med Sci; 2018 Jun; 34(6):335-340. PubMed ID: 29747777
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder.
Wild PJ; Herr A; Wissmann C; Stoehr R; Rosenthal A; Zaak D; Simon R; Knuechel R; Pilarsky C; Hartmann A
Clin Cancer Res; 2005 Jun; 11(12):4415-29. PubMed ID: 15958626
[TBL] [Abstract][Full Text] [Related]
18. Clinical Parameters Outperform Molecular Subtypes for Predicting Outcome in Bladder Cancer: Results from Multiple Cohorts, Including TCGA.
Morera DS; Hasanali SL; Belew D; Ghosh S; Klaassen Z; Jordan AR; Wang J; Terris MK; Bollag RJ; Merseburger AS; Stenzl A; Soloway MS; Lokeshwar VB
J Urol; 2020 Jan; 203(1):62-72. PubMed ID: 31112107
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of colorectal cancer subtypes and cell lines using deep learning.
Ronen J; Hayat S; Akalin A
Life Sci Alliance; 2019 Dec; 2(6):. PubMed ID: 31792061
[TBL] [Abstract][Full Text] [Related]
20. miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer.
Nordentoft I; Birkenkamp-Demtroder K; Agerbæk M; Theodorescu D; Ostenfeld MS; Hartmann A; Borre M; Ørntoft TF; Dyrskjøt L
BMC Med Genomics; 2012 Sep; 5():40. PubMed ID: 22954303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
